EcoDrugPlus

Serpin Peptidase Inhibitor, Clade C (Antithrombin), Member 1

Ensembl ID : ENSIPUG00000024827
Gene Symbol: SERPINC1
3 Cross references
201 Possible Orthologues:

Serum Amyloid P-Component

Ensembl ID : ENSIPUG00000024292
Gene Symbol: LOC108258898
3 Cross references
511 Possible Orthologues:

Serum Amyloid P-Component

Ensembl ID : ENSIPUG00000024296
Gene Symbol: LOC108258899
3 Cross references
511 Possible Orthologues:

Si:dkey-211g8.6

Ensembl ID : ENSIPUG00000008802
Gene Symbol: SI:DKEY-211G8.6
1 Cross references
320 Possible Orthologues:

Sigma Non-Opioid Intracellular Receptor 1

Ensembl ID : ENSIPUG00000024867
Gene Symbol: SIGMAR1
3 Cross references
205 Possible Orthologues:

Sirtuin 1

Ensembl ID : ENSIPUG00000018577
Gene Symbol: SIRT1
3 Cross references
155 Possible Orthologues:

Smoothened, Frizzled Class Receptor

Ensembl ID : ENSIPUG00000023084
Gene Symbol: SMO
3 Cross references
204 Possible Orthologues:

Sodium Channel, Voltage Gated, Type V-Like, Alpha B

Ensembl ID : ENSIPUG00000024742
Gene Symbol: SCN5LAB
3 Cross references
265 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Viii, Alpha Subunit A

Ensembl ID : ENSIPUG00000006458
Gene Symbol: SCN8AA
3 Cross references
263 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Viii, Alpha Subunit B

Ensembl ID : ENSIPUG00000020075
Gene Symbol: SCN8AB
3 Cross references
263 Possible Orthologues:

Sodium Channel, Voltage Gated, Type Xii, Alpha A

Ensembl ID : ENSIPUG00000018236
Gene Symbol: SCN12AA
3 Cross references
248 Possible Orthologues:

Sodium/potassium-Transporting Atpase Subunit Alpha-1

Ensembl ID : ENSIPUG00000007549
Gene Symbol: LOC108258575
3 Cross references
147 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).